Sutro Biopharma price to book ratio STRO

Market value divided by the book value of the company's net assets, since 2019.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 2.1×; May 2025
8-year median: 2.0×
8-year range: 0.8× to 4.4×
Peer median: 2.5×

Sutro Biopharma's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in May 2025, at 2.1×.

On the days it had one over the last 8 years, its median was 2.0×, from 0.8× in Nov 2023 to 4.4× in Jan 2021.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2025	2.1×	1.0×	2.1×
2024	1.4×	1.4×	3.7×
2023	2.3×	0.8×	2.3×
2022	2.0×	0.8×	2.0×
2021	2.4×	2.3×	4.4×
2020	3.4×	1.5×	3.6×
2019	2.3×	1.5×	2.3×

Against its peers

Companies in Healthcare nearest Sutro Biopharma's size, closest first, today.

Company	Price to book ratio
STROSutro Biopharma	n/m
PDEXPro DEX	4.2×
PLXProtalix BioTherapeutics	2.9×
NATRNatures Sunshine Products	1.3×
ELMDElectromed	4.1×
UTMDUtah Medical Products	1.9×
KEQUKewaunee Scientific	1.3×
ICCCImmucell	3.0×
INFUInfuSystem	4.7×
LFVNLifevantage	2.2×
SPROSpero Therapeutics	1.5×
Peer median	2.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Sutro Biopharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.